Table 2 Comparison of laboratory parameters and baseline characteristics among the three groups of SFTS patients
From: The associations between fasting blood glucose levels and mortality of SFTS in patients
Variables | Group A (n = 19) | Group B (n = 18) | Group C (n = 40) | p-Value |
|---|---|---|---|---|
Age, years, median (IQR) | 62.0 (51.0–68.0) | 58.5 (53.8–70.0) | 66.0 (63.0–70.0) | 0.059 |
Sex | ||||
Female, n (%) | 8 (42.1) | 8 (44.4) | 26 (65.0) | 0.158 |
Male, n (%) | 11 (57.9) | 10 (55.6) | 14 (35.0) | |
Onset symptoms | ||||
Fever, n (%) | 19 (100) | 17 (94.4) | 39 (97.5) | 0.568 |
Cough, n (%) | 6 (31.6) | 8 (44.4) | 18 (45.0) | 0.144 |
Expectoration, n (%) | 3 (15.8) | 5 (27.8) | 16 (40.0) | 0.162 |
Muscular soreness, n (%) | 11 (57.9) | 12 (66.7) | 16 (40.0) | 0.131 |
Fatigue, n (%) | 15 (78.9) | 11 (61.1) | 32 (80.0) | 0.278 |
Diarrhoea, n (%) | 7 (36.8) | 10 (55.6) | 20 (50.0) | 0.491 |
Time from onset to admission, median (IQR), d | 7.0 (5.0–8.0) | 5.0 (4.0–7.0) | 5.0 (5.0–7.0) | 0.357 |
FBG (mmol/L) | 4.91 (4.42–5.22) | 6.16 (5.96–6.54) | 10.23 (8.71–12.93) | < 0.01 |
Leukocytes (×109/L) | 4.02 (1.63–5.07) | 2.80 (1.93–3.34) | 1.94 (1.30–2.93) | 0.026 |
Neutrophils (× 109/L) | 2.06 (0.87–2.73) | 1.38 (0.94–2.07) | 1.12 (0.73–1.98) | 0.159 |
Platelet (×109/L) | 54.0 (34.0–69.0) | 45.0 (40.7–73.0) | 40.5 (30.0–59.0) | 0.108 |
CRP (mg/L) | 3.9 (0.8–10.43) | 3.57 (0.69–6.57) | 3.1 (1.15–10.17) | 0.635 |
Procalcitonin (mg/L) | 0.11 (0.05–0.45) | 0.09 (0.06–0.15) | 0.20 (0.11–0.37) | 0.067 |
IL-1β (pg/mL) | 6.85 (5.0–11.95) | 9.02 (5.0–18.8) | 9.74 (5.0–16.6) | 0.489 |
IL-2R (U/mL) | 955 (748–1353) | 1151 (941–1369) | 1352 (1031–1678) | 0.106 |
IL-6 (pg/mL) | 7.58 (3.2–24.0) | 12.8 (6.63–59.9) | 13.0 (7.14–34.3) | 0.172 |
IL-8 (pg/mL) | 17.3 (12.8–28.3) | 25.5 (17.05–50.5) | 27.2 (17.7–47.9) | 0.057 |
IL-10 (pg/mL) | 11.65 (7.2–27.3) | 24.9 (11.0–56.9) | 61.7 (43.2–139.0) | 0.0001 |
TNF-α (pg/mL) | 18.2 (13.3–27.0) | 16.6 (14.2–25.5) | 23.2 (17.0–43.0) | 0.042 |
AST (U/L) | 110 (84.0–147) | 125.5 (98.0–204.7) | 227.5 (101.7–425.5) | 0.021 |
ALT (U/L) | 78.0 (39.0–89.0) | 69.5 (44.5–98.5) | 86.5 (54.7–120.5) | 0.422 |
CRE (μmol/L) | 72.8 (53.6–86.2) | 83.9 (59.5–101.8) | 71.5 (60.1–91.3) | 0.592 |
LDH (U/L) | 723 (531–1314) | 798 (500–1353) | 1177 (754–2322) | 0.059 |
CK (U/L) | 239 (93–686) | 362 (107–1679) | 406 (158–1007) | 0.427 |
PT (S) | 13.7 (12.7–14.5) | 13.3 (12.8–13.6) | 13.5 (12.7–14.2) | 0.477 |
APTT (S) | 45.7 (39.9–58.9) | 51.2 (48.7–54.1) | 54.5 (47.5–65.3) | 0.184 |
FIB (g/L) | 2.98 (2.6–3.85) | 2.77 (2.42–3.25) | 2.78 (2.35–3.46) | 0.429 |
D-Dimer (μg/ml) | 1.54 (1.24–1.89) | 2.47 (1.44–3.34) | 3.84 (1.75–8.93) | 0.003 |
FDP (μg/ml) | 4.92 (3.55–5.78) | 6.28 (4.03–11.31) | 11.79 (6.01–30.58) | 0.002 |
Serum amyalse (U/L) | 81 (30–353) | 88.5 (34–458) | 109 (43–681) | 0.264 |
Serum lipase (U/L) | 518 (44–2000) | 559 (58–2000) | 625 (27–2000) | 0.416 |
Secondary infection, n (%) | 8 (42.1) | 5 (27.8) | 22 (55.0) | 0.148 |
Median length of in-hospital stay (days), median (IQR) | 10.0 (9.0–12.0) | 10.5 (6.5–15.0) | 11.0 (8.0–16.0) | 0.465 |
Mortality (n, %) | 5.3% | 22.2% | 27.5% | 0.14 |